<DOC>
	<DOC>NCT00294515</DOC>
	<brief_summary>This study will determine the relative efficacy and safety of up to 100 days Valcyte prophylaxis relative to up to 200 days Valcyte prophylaxis when given for the prevention of CMV disease in high-risk (D+/R-) kidney allograft recipients. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>â‰¥ 16 years of age CMV seronegative recipient of primary or secondary renal allograft from a living or cadaveric seropositive donor Adequate hematological and renal function Patients and partners must agree to maintain effective birth control for 90 days following cessation of study medication CMV disease, or receipt of antiCMV therapy within 30 days prior to screening Multiorgan transplant recipient Hepatitis B, hepatitis C or HIV positive Women who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>